Literature DB >> 14955985

Mepacrine and rheumatoid arthritis.

A FREEDMAN, F BACH.   

Abstract

Entities:  

Keywords:  ARTHRITIS, RHEUMATOID/therapy; QUINACRINE/therapeutic use

Mesh:

Substances:

Year:  1952        PMID: 14955985     DOI: 10.1016/s0140-6736(52)92481-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year.

Authors:  A FREEDMAN; V L STEINBERG
Journal:  Ann Rheum Dis       Date:  1960-09       Impact factor: 19.103

2.  The value of chloroquine in rheumatoid disease: a four-year study of continuous therapy.

Authors:  A W BAGNALL
Journal:  Can Med Assoc J       Date:  1957-08-01       Impact factor: 8.262

3.  Chloroquine and rheumatoid arthritis; a short-term controlled trial.

Authors:  A FREEDMAN
Journal:  Ann Rheum Dis       Date:  1956-09       Impact factor: 19.103

Review 4.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

5.  Marrow transplantation for severe aplastic anemia associated with exposure to quinacrine.

Authors:  I Schmid; C Anasetti; F B Petersen; R Storb
Journal:  Blut       Date:  1990 Aug-Sep

Review 6.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.

Authors:  Katerina Gurova
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

7.  A study of the effects of amodiaquine on the guinea-pig isolated ileum.

Authors:  J Fontaine; J P Famaey; J Reuse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

8.  Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.

Authors:  Reza Ehsanian; Carter Van Waes; Stephan M Feller
Journal:  Cell Commun Signal       Date:  2011-05-15       Impact factor: 5.712

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.